Investigation of the efficacy of Esomeprazole for 8 weeks to the proton pomp inhibitor (PPI)-resistant gastro-esophageal reflux disease (GERD) patients

Investigation of the efficacy of Esomeprazole for 8 weeks to the proton pomp inhibitor (PPI)-resistant gastro-esophageal reflux disease (GERD) patients - Investigation of the efficacy of Esomeprazole for 8 weeks to the gastro-esophageal reflux disease (GERD) patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012000

Enrollment

Registered

2013-10-15

Start date

2013-08-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastroesophageal

Interventions

PPI-resistant GERD patients will be separated two groups

1.changing to Esomeprazole. PPI-resistant GERD patients will be separated two groups

2.adding mosapride to Rabeprazole,Lansoprazole.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Over 20 years GERD patients prescribed PPI (Rabeprazole 10mg or Lansoprazole 15mg) for more than 8 weeks 2.The patients having symptom of GERD

Exclusion criteria

Exclusion criteria: 1. Severe liver function failure (AST or ALT >100IU/l) 2. Severe heart failure 3. Patients with malignant disease 4. Patients with HIV positive or AIDS 5. Patients received vagolysis 6. Patients received surgery with upper gastrointestinal tract 7. Patients prescribed prohibited concomitant drugs 8. Patients having allergy for Esomeprazole or the similar drugs 9. Patients having difficulty of writing questionnaire sheets 10. Patients who are pregnant 11. Nursing wemen

Design outcomes

Primary

Measure	Time frame
Improvement of QOL score using QOLRAD-J questionnaire Improvement of symptom score using GERDQ questionnaire	—

Countries

Japan

Contacts

Public ContactTatsuya Toyokawa

NationalOrganizationHospital Fukuyama medical center Department of Gastroenterology

toyotatu@kmail.plala.or.jp084-922-0001

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026